Delivery Order SPE2DB24D2011-SPE2DB25FBRQP
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $29,860.78 for Dupixent 300 mg/2 ml syringes on August 15, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price contract, which is not set-aside, will be performed at the company's corporate office in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, asthma, and other inflammatory conditions, making...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Dupixent 300 mg/2 mL syringes with a ceiling value of $6,837.84. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of July 24, 2025, with performance taking place at the vendor's corporate office in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Dupixent 300 mg/2 ml syringes with a ceiling value of $6,837.84. This delivery order represents a firm fixed price contract with no set-aside designation, meaning it was competitively awarded. The order is scheduled for completion by August 1, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Dupixent is a biologic medication...
- The Defense Logistics Agency awarded a delivery order valued at $33,470.72 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml syringes on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a monoclonal antibody used to treat conditions including atopic dermatitis,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Dupixent 300 mg/2 ml syringes with a contract value of $42,767.05. This non-set-aside, firm fixed-price delivery order is scheduled for completion by August 26, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $6,837.84 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL syringes on July 23, 2025, with completion scheduled for July 24, 2025. This competitively awarded, firm fixed-price delivery order was issued without set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic immunosuppressant medication commonly used to...
- The Defense Logistics Agency awarded a delivery order valued at $45,626.04 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL syringes on August 18, 2025, with completion scheduled for August 19, 2025. This firm fixed price contract represents a non-competitive delivery order issued under an existing contract vehicle and will be performed at the vendor's Conshohocken, Pennsylvania location. Dupixent is a biologic medication used to treat eczema, asthma, and other...
- The Defense Logistics Agency awarded a $14,845.54 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml syringes on July 23, 2025, with completion scheduled for July 24, 2025. This competitively awarded, firm fixed price contract contains no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication primarily used to treat moderate-to-severe atopic dermatitis,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml syringes valued at $2,022.79 on August 4, 2025, with completion scheduled for August 5, 2025. This non-set-aside, competitively awarded contract employs firm fixed-price terms and is performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a prescription biologic medication used to treat moderate-to-severe eczema, asthma, and other allergic...
- The Defense Logistics Agency awarded a delivery order valued at $10,923.48 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml syringes on July 29, 2025, with an ultimate completion date of July 30, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation. The pharmaceutical product will be delivered from AmerisourceBergen's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication primarily used to treat...
- SPE2DB24D2011Indefinite Delivery Contract
- SPE2DB24D2011-SPE2DB25FBRQPDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Dupixent 300 mg/2 mL syringes with a ceiling value of $37,709.53. This is a firm fixed price delivery order with an ultimate completion date of August 25, 2025, to be performed at the contractor's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, moderate-to-severe eosinophilic asthma, and other inflammatory conditions, making it a critical pharmaceutical asset for military healthcare systems. This delivery order is executed under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen has demonstrated consistent capability to meet federal procurement requirements and serves as a prime vendor for supplying a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The company's role as a critical federal medical procurement vendor reflects its established position within the Defense Logistics Agency's Medical Supply Chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $37.7k | 8/22/25 |